THE DYNAMICS OF MARKERS OF FIBROSIS WITH THE FEATURES OF METABOLIC PHENOTYPES IN PATIENTS WITH MYOCARDIAL INFARCTION

Abstract

The features of the dynamics of serum markers of fibrosis, myocardial remodeling and progression of chronic insufficiency: C-terminal propeptide procollagen type I (PICP) and N-terminal propeptide procollagen type III (PIIINP) in patients with ST-segment elevation myocardial infarction were evaluated taking into account the peculiarities of the metabolic phenotype of patients. The study included 83 patients with left ventricular ejection fraction ≥50% of 120 patients admitted to the hospital with a diagnosis of ST-segment elevation myocardial infarction. Depending on the metabolic phenotype, the patients were divided into two groups: a group of 23 patients with normal body weight and a group of 60 patients with overweight and obesity of varying severity. The results indicate the relationship of serum markers of fibrosis of the myocardium with echocardiogram indicators, and myocardial remodeling in patients with myocardial infarction with ST-segment elevation. Isolation of patients with normal weight showed a general tendency to reduce the concentration of fibrosis markers regardless of the duration of the disease. The reverse trend allowed us to observe the selection of a group of patients with overweight or obesity. The obtained significant correlation between markers of myocardial fibrosis, data, echocardiogram, and anamnesis.

Keywords

myocardial fibrosis / C-terminal propeptide of procollagen I type / N-terminal propeptide of procollagen III type / obesity / chronic heart failure

References

[1] Ng M., Fleming T., Robinson M., Thomson B., Graetz N., Margono C. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384(9945): 766-81. doi:10.1016/S0140-6736(14)60460-8

[2] Муромцева Г.А., Концевая А.В., Константинов В.В., Артамонова Г.В., Гатагонова Т.М., Дупляков Д.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014; 13(6): 4-11. https://doi.org/10.15829/1728-8800-2014-6-4-11

[3] Jungheim E.S., Travieso J.L., Carson K.R., Moley K.H. Obesity and reproductive function. Obstetrics and gynecology clinics of North America. 2012; 39(4): 479-93. doi: 10.1016/j.ogc.2012.09.002

[4] Alam M., Siddiqui S., Lee V.V., Elayda M.A., Nambi V., Yang E.Y. et al. Isolated coronary artery bypass grafting in obese individuals: a propensity matched analysis of outcomes. Circ J. 2011; 75(6): 1378-85.

[5] Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New Engl J Med. 2006; 355(3): 251-9. doi: 10.1056/nejmoa052256

[6] Шилов С.Н., Тепляков А.Т., Яковлева И.В., Попова А.А., Березикова Е.Н., Гракова Е.В., и др. Клиническая и патологическая взаимосвязь хронической сердечной недостаточности, сахарного диабета 2 типа и остеопороза. Комплексные проблемы сердечно-сосудистых заболеваний. 2018; 7(1): 6-13. https://doi.org/10.17802/2306-1278-2018-7-1-6-13

[7] Миклишанская С.В., Мазур Н.А., Шестакова Н.В. Механизмы формирования миокардиального фиброза в норме и при некоторых сердечно-сосудистых заболеваниях, методы его диагностики. Медицинский совет. 2017; (12): 75-81. https://doi.org/10.21518/2079-701X-2017-12-75-81

[8] Husain-Syed F., McCullough P.A., Birk H-W., Renker M., Brocca A., Seeger W. et al. Cardio-Pulmonary-renal interactions. J Am Coll Cardiol. 2015; 65 (22): 2433-48. doi:10.1016/j.jacc.2015.04.024

[9] Фомин И.В. Эпидемиология хронической сердечной недостаточности в Европейской части Российской Федерации. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа; 2010: 5-18.

[10] Соломахина Н.И., Беленков Ю.Н., Варшавский В.А. Фиброз миокарда при систолической и диастолической хронической сердечной недостаточности. М.: ИД «МЕДПРАКТИКА-М»; 2014.

[11] Kenchaiah S., Pocock S.J., Wang D., Finn P.V., Zornoff L.A., Skali H. et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007; 116(6): 627-36. doi:10.1161/CIRCULATIONAHA.106.679779

[12] Horwich T.B., Broderick S., Chen L., McCullough P.A., Strzelczyk T., Kitzman D.W., et al. Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure. Am J Cardiol. 2011; 108(12): 1754-9. doi:10.1016/j.amjcard.2011.07.051

[13] Kapoor J.R., Heidenreich P.A. Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship. Am Heart J. 2010; 159(1):75-80. doi: 10.1016/j.ahj.2009.10.026

[14] Fonarow G.C., Srikanthan P., Costanzo M.R., Cintron G.B., Lopatin M. ADHERE Scientific Advisory Committee and Investigators. An obesity paradox in acute heart failure: analysis of body mass index and in-hospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J. 2007; 153(1): 74-81. doi:10.1016/j.ahj.2006.09.007

[15] Sharma A., Lavie C.J., Borer J.S., Vallakati A., Goel S., Lopez-Jimenez F. et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015; 115(10): 1428-34. doi: 10.1016/j.amjcard.2015.02.024.

[16] Lok S.I., Nous F.M., van Kuik J., van der Weide P., Winkens B., Kemperman H. et al. Myocardial fibrosis and profibrotic marcers in end-stage heart failure patients during continuous-flow left ventricular assist device support. European Journal of Cardio-Thoracic Surgery. 2015; 48 (3): 407-15. doi:10.1093/ejcts/ezu539

[17] Parul U. Gandhi, Hanna K. Gaggin, Margaret M. Redfield, Horng H. Chen, Susanna R. Stevens. et al. Insulin-like growth factor-binding protein-7 as a biomarker of diastolic dysfunction and functional capacity in heart failure with preserved ejection fraction results from the RELAX trial. JACC. Heart failure. 2016; 4(11): 860-9. doi: 10.1016/j.jchf.2016.08.002

[18] Копьева К.В., Гракова Е.В., Тепляков А.Т. Новые маркеры сердечной недостаточности: значение для диагности и прогнозирования NT-proBNP и интерлейкиновых рецепторов - членов семейства ST2. Комплексные проблемы сердечно-сосудистых заболеваний. 2018; 7(1): 94-101. https://doi.org/10.17802/2306-1278-2018-7-1-94-101

[19] Lopez B., Gonzales A., Querejeta R., Zubillaga E., Larman M., Diez J. Galectine-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Failure. 2015; (17): Р.385-92. doi:10.1002/ejhf.246.

[20] Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H. et al. 2013 ACCEFT/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128(16): 240-27. doi:10.1161/cir.0b013e31829e8776.

[21] Тарловская Е.И. Рекомендации общества специалистов по сердечной недостаточности; что нового? Ремедиум. 2014; 2(122): 21-5.

[22] Овчинников А.Г., Ожерельев М.В., Агеев Ф.Т. Фиброз левого желудочка: патогенез, диагностика, лечение. Неотложная кардиология. 2015; (4): 11-26.

[23] Murray D.B., Gardner J.D., Brower G.L., Janicki J.S. Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation and myocardial remodeling in rats. Am J Physiol Heart Circ Physiol. 2004; 287(5): 2295-9. doi: 10.1152/ajpheart.00048.2004

[24] Бокерия О.Л., Аверина И.И. Клиническое применение технологий анализа функции миокарда. Оценка гемодинамики маркеров асимптомной дисфункции фиброза миокарда. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2014; 15 (6): 6-19

[25] Neilan T.G., Coelho-Filho O.R., Shah R.V., Abbasi S.A., Heydari B., Watanabe E. et al. Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. J Am Coll Cardiol Img. 2013; (6): 672-83. doi: 10.1016/j.jcmg.2012.09.020

[26] Li O., Liu X, Wei J. Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent. Biochem Biophys Res Comm. 2014; 452(3): 497-502. doi: 10.1016/j.bbrc.2014.08.109

[27] Wu J., Xia S., Kalionis B., Wan W., Sun T. et al. The role of oxida-tive stress and inflammation in cardiovascular aging. BioMed Res Int. 2014; 2014: 615312. doi: 10.1155/2014/615312

[28] Boon R.A., Iekushi K., Lechner S., Seeger T., Fischer A., Heydt S. et al. Micro-RNA-34a regulates cardiac ageing and function. Nature. 2013; 495(7439): 107-10. doi: 10.1038/nature11919

[29] Dzeshka M.S., Lip G.Y., Snezhitskiy V., Shantsila E. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. JACC. 2015; 66(8): 943-59. doi: 10.1016/j.jacc.2015.06.1313

[30] Pernot M., Lee W.N., Bel A., Mateo P., Couade M., Mickaël Tanter. et al. Shear Wave Imaging of Passive Diastolic Myocardial Stiffness Stunned Versus Infarcted Myocardium. JACC Cardiovasc Imaging. 2016; 9(9): 1023-30. doi: 10.1016/j.jcmg.2016.01.022

[31] Flachskampf F.A., Biering-Sørensen T., Solomon S.D., Duvernoy O., Bjerner T., Smiseth O.A. Cardiac Imaging to Evaluate Left Ventricular Diastolic Function. JACC Cardiovasc Imaging. 2015;8(9):1071-93. doi: 10.1016/j.jcmg.2015.07.004

RIGHTS & PERMISSIONS

Eco-Vector